Premium
Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology
Author(s) -
Oude Munnink TH,
Henstra MJ,
Segerink LI,
Movig KLL,
BrummelhuisVisser P
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.211
Subject(s) - monoclonal antibody , medicine , therapeutic drug monitoring , pharmacokinetics , drug , dosing , malignant disease , pharmacology , monoclonal , disease , immunology , disease monitoring , oncology , antibody , cancer
Lack of response to monoclonal antibodies (mAbs) has been associated with inadequate mAb serum concentrations. Therapeutic drug monitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability of mAb pharmacokinetics, summarizes exposure‐response data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb‐TDM in inflammatory disease, and provides hurdles and required future steps for further implementing mAb‐TDM.